28.10.2010 • News

DuPont Quarterly Profit Beats Street

DuPont posted a higher-than-expected quarterly profit as sales rose in all six business units and across the globe.

During the third quarter, the company earned $367 million, or 40 cents per share, compared with $409 million, or 45 cents per share, a year earlier.

Analysts on average expected earnings of 34 cents per share, according to Thomson Reuters I/B/E/S.

Revenue rose 14.8% to $7 billion. Analysts expected $6.72 billion.

For 2010, DuPont now expects to earn $3.10 per share, excluding items, up from a previous estimate of $2.90 to $3.05. Analysts were expecting $3.04.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.